Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

키워드

참고문헌 (26)

1. Harris NL, "A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group", Blood, 84, pp.1361~1392 (1994)
2. Harris NL, "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues : report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997", J Clin Oncol, 17, pp.3835~3849 (1999)
3. Armitage JO, "New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project", J Clin Oncol, 16, pp.2780~2795 (1998)
4. Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
5. Habermann TM, "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma", J Clin Oncol, 24, pp.3121~3127 (2006)
6. Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60)", Lancet Oncol, 9, pp.105~116 (2008)
7. Pfreundschuh M, "CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial(MInT)Group", Lancet Oncol, 7, pp.379~391 (2006)
8. Sehn LH, "Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia", J Clin Oncol, 23, pp.5027~5033 (2005)
9. McLaughlin P, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program", J Clin Oncol, 16, pp.2825~2833 (1998)
10. Alduaij W, "The future of anti-CD20 monoclonal antibodies: are we making progress?", Blood, 117, pp.2993~3001 (2011)
11. Beers SA, "Type II(tositumomab)anti-CD20 monoclonal antibody out performs type I(rituximab-like)reagents in B-cell depletion regardless of complement activation", Blood, 112, pp.4170~4177 (2008)
12. Cartron G, "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene", Blood, 99, pp.754~758 (2002)
13. Shibata-Koyama M, "Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils", Exp Hematol, 37, pp.309~321 (2009)
14. Burger JA, "The microenvironment in mature B-cell malignancies : a target for new treatment strategies", Blood, 114, pp.3367~3375 (2009)
15. Winkler U, "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody(rituximab, IDEC-C2B8)", Blood, 94, pp.2217~2224 (1999)
16. Byrd JC, "Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells : association with increased infusion-related side effects and rapid blood tumor clearance", J Clin Oncol, 17, pp.791~795 (1999)
17. Lenz HJ, "Management and preparedness for infusion and hypersensitivity reactions", Oncologist, 12, pp.601~609 (2007)
18. Cheson BD, "Tumor lysis syndrome : an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia", J Clin Oncol, 16, pp.2313~2320 (1998)
19. Campo E, "The 2008 WHO classification of lymphoid neoplasms and beyond : evolving concepts and practical applications", Blood, 117, pp.5019~5032 (2011)
20. International Non-Hodgkin’s Lymphoma Prognostic Factors Project, "A predictive model for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 329, pp.987~994 (1993)
21. Hong J, "Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma", Support Care Cancer, 21, pp.1145~1152 (2013)
22. Sharma R, "Inflammatory(B)symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma(NHL)patients : analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO", BMC Cancer, 9, pp.153~ (2009)
23. Legouffe E, "C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma", Leuk Lymphoma, 31, pp.351~357 (1998)
24. Yan Y, "Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma", J Clin Oncol, 13, pp.1336~1342 (1995)
25. van der Kolk LE, "Complement activation plays a key role in the side-effects of rituximab treatment", Br J Haematol, 115, pp.807~811 (2001)
26. Lim LC, "Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia", J Clin Oncol, 17, pp.1962~1963 (1999)

관련 논문AI추천